app

New Investigational Fertility Pill; Biden Wants Lower GLP-1 Prices; BVO to Be Banned

— News and commentary from the endocrinology world

MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

The investigational pill OXO-001 boosted pregnancy rates 10.6 percentage points higher than placebo in women who underwent in a phase II trial, developer Oxolife announced.

There were clinically meaningful reductions in major atherogenic blood lipids after that appeared to be independent of weight loss. (JAMA Surgery)

President Biden to slash the prices of their GLP-1 receptor agonists. (Reuters)

Upon reaching age 65, when most patients enroll in Medicare, quarterly increased by an average of $23.04. (JAMA Network Open)

Compared with bisphosphonates, was associated with a reduced risk of developing type 2 diabetes, all-cause mortality, and microvascular complications in a large global database. (Diabetes, Obesity and Metabolism)

Is in menopausal women? (The Guardian)

Turner Syndrome-associated diabetes has features of both type 1 and type 2, according to researchers in the.

The FDA plans to (BVO) in food and beverages by next month. BVO exposure may be , the agency noted.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.